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R
ecent suggestions to revise guidelines that recommend
extending the time for revaccination beyond 10 years
may be based on insufficient and conflicting evidence of
persistence of immunity (1,2). The evidence that cell-
mediated immunity and neutralizing antibody persist after
one vaccination is conflicting (2–5). This residual immuni-
ty is often low, and its protective activity in vivo is unclear.
Similarly, in vivo reports of durable immunity to smallpox
(1) were not sufficiently controlled, and short persistence
of resistance to dermal challenge with the antigenically
related vaccinia virus has been reported (3,6).
We confirmed the previous report (5) that the residual
antivaccinia virus titers of serum samples from singly vac-
cinated adults are low (average 32) (Table). The titer of
normal commercial immunoglobulin (Ig) (Panglobulin)
(11 times concentrated sera) was 150 U/mL, which when
calculated to include the 11-fold concentration, confirms
the low residual titers.
The titers of the control, unvaccinated persons, aver-
aged 14, raising questions about the importance and speci-
ficity of the residual antibody in vaccinated persons. We
determined that the persistent neutralizing activity is main-
ly IgG antibody in serum from both single-vaccinated per-
sons and ordinary commercial IgG, since sequential
absorption with protein G beads and anti-IgG beads
reduced the titers 80%. However, the neutralizing activity
in unvaccinated control serum may not be mainly IgG anti-
body since neutralizing activity was reduced by an average
of 48%, favoring nonspecific inhibitors. Studies of these
nonspecific inhibitors and possible cross-immunizing anti-
gens in the environment should be conducted to explain
the occurrence of neutralizing activity in serum of unvac-
cinated persons. 
To determine whether the low residual titers in sera
from single vaccinated persons protected in vivo against a
systemic infection, mice were pretreated subcutaneously
with 1 mL of either 1) serum from a single-vaccinated
study participant containing the low 10 U/mL neutralizing
activity (patient A), 2) serum from a single-vaccinated per-
son containing the higher 43 U/mL (patient E), or 3) nor-
mal commercial Ig containing 150 U/mL and challenged
24 hours later with one LD100 vaccinia virus, strain IHD-E,
intraperitoneally. The 1 mLof serum injected into the mice
is estimated to provide its original titer in the mouse. The
lowest titer serum (10 U/mL) did not protect the mice
against lethal systemic infection, whereas the highest titer
serum (43 U/mL) and the commercial Ig (150 U/mL) pro-
tected 50% of the mice. Thus, the levels of residual anti-
body in vaccinated persons are either not protective or only
partially protective in mice. Consistent with the reported
protection by the higher levels of antibody, vaccinia
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Table. Residual vaccinia virus neutralizing titers of serum from 







  A  47  10 
  B  50  26 
  C  45  27 
  D  40  34 
  E  40  43 
Ordinary commercial 
immunoglobulin (Panglobulin) 
  150 
Unvaccinated persons     
  H6  —
a  <10 
  H9  —  <10 
  C2  —  <10 
  C4  —  <10 
  H1  —  10 
  H2  —  10 
  H13  —  10 
  C1  —  10 
  C3  —  10 
  H7  —  10 
  HL  —  20 
  H3  —  20 
  H4  —  20 
  H5  —  20 
  H10  —  20 
  H11    —  20 
  H12  —  20 
  C7  —  20 
  H8  —  30 
a—, Not applicable. immune globulin (VIG), which contains 500 neutralizing
U/mL, is effective under some conditions (7–10). As a pos-
itive control for protection in this animal model, 100 µg of
the interferon inducer Poly I:CLC protected 100% of the
mice. Undetermined and requiring study is whether active
immunity might be protective through an anamnestic
response. The animal models of poxvirus infection have
been used to evaluate immunity, but no generally estab-
lished laboratory surrogate exists for immunity to small-
pox virus itself. Persistence of effective humoral immuni-
ty after a single vaccination and its ability to effectively
protect in vivo remain questionable.
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